AC
TARA icon

Armistice Capital’s Protara Therapeutics TARA Stock Holding History

Armistice Capital’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-520,000
Closed -$1.08M – 319
2024
Q2 		$1.08M Buy
+520,000
New +$1.52M 0.01% 160

Other funds holding TARA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Armistice Capital's TARA Position: Q3 2024 in Review

Armistice Capital sold out of Protara Therapeutics (TARA) in Q3 2024, closing a stake of 520,000 shares — an estimated $1.08M sold.

Armistice Capital first reported a position in TARA in Q2 2024 and held it in 1 quarter. The position peaked at $1.08M in Q2 2024. 35 funds tracked by Wall St. Rank hold TARA as of Q3 2024.

  • Armistice Capital reported no remaining Protara Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Armistice Capital sold 520,000 Protara Therapeutics shares in Q3 2024, an estimated $1.08M.
  • Armistice Capital first reported a position in Protara Therapeutics in Q2 2024 and held it in 1 quarter.
  • Armistice Capital's Protara Therapeutics position peaked at $1.08M in Q2 2024.
  • 35 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2024.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.